A prompt graft-versus-thalassemia effect upon withdrawal of cyclosporine A in a child who received allogeneic peripheral blood stem cell transplantation

Mixed chimerism and graft loss in pediatric recipients of an alemtuzumab-based reduced-intensity conditioning regimen for non-malignant disease

“…This approach is standard in the setting of malignant disease . In the non‐malignant setting, however, where MC is not necessarily a harbinger of impending disease recurrence, this approach is less established . Indeed, in the context of RIC HCT for acquired severe aplastic anemia, tapering of IST has been observed to correlate with decreasing donor chimerism, not the reverse .…”

Escalating doses of donor lymphocytes for incipient graft rejection following SCT for thalassemia

“…3 In case of graft rejection, patients can be offered either conservative medical treatment or a second transplantation, balancing the risk of morbidity and mortality. 5 Alternatively, a modulation of the donor immune system can be attempted during MC either by escalating immunosuppression to decrease the host-versus-donor alloreactive potential or by increasing the donor-versus-host alloimmunity either by rapid discontinuation of immunosuppression priced by a higher risk of GVHD [6][7][8] or by infusion of immunocompetent donor cells. The use of donor lymphocytes infusion (DLI) has been well described to treat disease relapse for several haemato-oncologic disorders in adults [9][10][11][12][13] and in children [14][15][16][17] such as chronic myeloid leukaemia, acute leukaemia, myelodysplasia, lymphoma, multiple myeloma, JMML and EBV associated lymphoproliferative disorders.…”